• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤中的异质性髓样细胞

Heterogeneous Myeloid Cells in Tumors.

作者信息

Dou Aixia, Fang Jing

机构信息

Department of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, Columbia, SC 29208, USA.

出版信息

Cancers (Basel). 2021 Jul 27;13(15):3772. doi: 10.3390/cancers13153772.

DOI:10.3390/cancers13153772
PMID:34359674
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8345207/
Abstract

Accumulating studies highlight a critical role of myeloid cells in cancer biology and therapy. The myeloid cells constitute the major components of tumor microenvironment (TME). The most studied tumor-associated myeloid cells (TAMCs) include monocytes, tumor-associated macrophages (TAMs), dendritic cells (DCs), cancer-related circulating neutrophils, tumor-associated neutrophils (TANs), and myeloid-derived suppressor cells (MDSCs). These heterogenous myeloid cells perform pro-tumor or anti-tumor function, exerting complex and even opposing effects on all stages of tumor development, such as malignant clonal evolution, growth, survival, invasiveness, dissemination and metastasis of tumor cells. TAMCs also reshape TME and tumor vasculature to favor tumor development. The main function of these myeloid cells is to modulate the behavior of lymphocytes, forming immunostimulatory or immunosuppressive TME cues. In addition, TAMCs play a critical role in modulating the response to cancer therapy. Targeting TAMCs is vigorously tested as monotherapy or in combination with chemotherapy or immunotherapy. This review briefly introduces the TAMC subpopulations and their function in tumor cells, TME, angiogenesis, immunomodulation, and cancer therapy.

摘要

越来越多的研究凸显了髓系细胞在癌症生物学和治疗中的关键作用。髓系细胞构成了肿瘤微环境(TME)的主要成分。研究最多的肿瘤相关髓系细胞(TAMCs)包括单核细胞、肿瘤相关巨噬细胞(TAMs)、树突状细胞(DCs)、癌症相关循环中性粒细胞、肿瘤相关中性粒细胞(TANs)和髓系来源的抑制细胞(MDSCs)。这些异质性髓系细胞发挥促肿瘤或抗肿瘤功能,对肿瘤发展的各个阶段,如肿瘤细胞的恶性克隆进化、生长、存活、侵袭、播散和转移,产生复杂甚至相反的影响。TAMCs还重塑TME和肿瘤血管系统以促进肿瘤发展。这些髓系细胞的主要功能是调节淋巴细胞的行为,形成免疫刺激或免疫抑制的TME信号。此外,TAMCs在调节癌症治疗反应中起关键作用。针对TAMCs作为单一疗法或与化疗或免疫疗法联合使用正在进行大力测试。本综述简要介绍了TAMC亚群及其在肿瘤细胞、TME、血管生成、免疫调节和癌症治疗中的功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579c/8345207/fc723d61121b/cancers-13-03772-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579c/8345207/25b4ab1da555/cancers-13-03772-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579c/8345207/4c6bec03b5ed/cancers-13-03772-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579c/8345207/c7fd09df2ce9/cancers-13-03772-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579c/8345207/5bc6c1eae0b2/cancers-13-03772-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579c/8345207/fc723d61121b/cancers-13-03772-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579c/8345207/25b4ab1da555/cancers-13-03772-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579c/8345207/4c6bec03b5ed/cancers-13-03772-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579c/8345207/c7fd09df2ce9/cancers-13-03772-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579c/8345207/5bc6c1eae0b2/cancers-13-03772-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579c/8345207/fc723d61121b/cancers-13-03772-g005.jpg

相似文献

1
Heterogeneous Myeloid Cells in Tumors.肿瘤中的异质性髓样细胞
Cancers (Basel). 2021 Jul 27;13(15):3772. doi: 10.3390/cancers13153772.
2
Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy.髓系衍生微环境的生物物理异质性调节癌症免疫治疗的耐药性。
Adv Drug Deliv Rev. 2022 Dec;191:114585. doi: 10.1016/j.addr.2022.114585. Epub 2022 Oct 21.
3
Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy.人类致癌病毒发病机制中促肿瘤髓样细胞:免疫治疗的潜在靶点
Cancer Cell Int. 2022 Oct 27;22(1):327. doi: 10.1186/s12935-022-02727-3.
4
CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.CD200-CD200R 通路在肿瘤免疫微环境调控及免疫治疗中的作用
Adv Exp Med Biol. 2020;1223:155-165. doi: 10.1007/978-3-030-35582-1_8.
5
Role of Tumor-Associated Myeloid Cells in Breast Cancer.肿瘤相关髓系细胞在乳腺癌中的作用。
Cells. 2020 Jul 27;9(8):1785. doi: 10.3390/cells9081785.
6
Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.璞玉浑金:利用肿瘤相关髓系细胞进行癌症治疗。
Front Immunol. 2018 Oct 8;9:2250. doi: 10.3389/fimmu.2018.02250. eCollection 2018.
7
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.纳米颗粒在癌症免疫治疗中的应用:靶向肿瘤微环境。
Bioact Mater. 2020 Dec 26;6(7):1973-1987. doi: 10.1016/j.bioactmat.2020.12.010. eCollection 2021 Jul.
8
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy.针对肿瘤驻留髓系细胞的癌症免疫治疗的新兴策略。
J Hematol Oncol. 2022 Aug 28;15(1):118. doi: 10.1186/s13045-022-01335-y.
9
Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.基于 89Zr 标记的抗 CD11b 抗体的脑胶质瘤浸润髓系细胞的免疫 PET 显像的临床前研究。
Mol Imaging Biol. 2020 Jun;22(3):685-694. doi: 10.1007/s11307-019-01427-1.
10
Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer.敌友难辨?癌症中靶向髓系细胞的最新策略
Front Cell Dev Biol. 2020 May 19;8:351. doi: 10.3389/fcell.2020.00351. eCollection 2020.

引用本文的文献

1
The predictive value of Naples prognostic score for patients with locally advanced non-small cell lung cancer undergoing surgery after neoadjuvant chemotherapy.那不勒斯预后评分对新辅助化疗后接受手术的局部晚期非小细胞肺癌患者的预测价值。
Front Immunol. 2025 May 22;16:1578896. doi: 10.3389/fimmu.2025.1578896. eCollection 2025.
2
Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets.胰腺癌中的免疫抑制性肿瘤微环境:机制与治疗靶点
Front Immunol. 2025 May 15;16:1582305. doi: 10.3389/fimmu.2025.1582305. eCollection 2025.
3
Tumor-infiltrating immune cells state-implications for various breast cancer subtypes.

本文引用的文献

1
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.一项 CSF-1R 抑制剂 LY3022855 联合度伐利尤单抗或替西木单抗治疗晚期实体瘤患者的 1a/1b 期临床试验。
Invest New Drugs. 2021 Oct;39(5):1284-1297. doi: 10.1007/s10637-021-01088-4. Epub 2021 Apr 14.
2
Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer.免疫检查点抑制剂:乳腺癌现有证据的综述和挑战。
Immunotherapy. 2021 May;13(7):587-603. doi: 10.2217/imt-2020-0283. Epub 2021 Mar 29.
3
Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma.
肿瘤浸润免疫细胞状态对不同乳腺癌亚型的影响
Front Immunol. 2025 May 14;16:1550003. doi: 10.3389/fimmu.2025.1550003. eCollection 2025.
4
Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39.肿瘤中由Th1细胞转化而来的调节性T细胞通过CD39抑制癌症免疫。
J Exp Med. 2025 Apr 7;222(4). doi: 10.1084/jem.20240445. Epub 2025 Feb 5.
5
Prognostic value of EMT-related genes and immune cell infiltration in thyroid carcinoma.甲状腺癌中 EMT 相关基因和免疫细胞浸润的预后价值。
Front Immunol. 2024 Nov 4;15:1463258. doi: 10.3389/fimmu.2024.1463258. eCollection 2024.
6
Predicting the prognosis of Wilms tumor by peripheral blood cells: a real-world study of more than 30 years.通过外周血细胞预测 Wilms 瘤的预后:一项超过 30 年的真实世界研究。
Ital J Pediatr. 2024 Nov 14;50(1):245. doi: 10.1186/s13052-024-01805-8.
7
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis.PD-L1 阻断免疫疗法重塑癌症诱导的紧急髓系生成。
Front Immunol. 2024 Oct 11;15:1386838. doi: 10.3389/fimmu.2024.1386838. eCollection 2024.
8
Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity.靶向CD206高表达巨噬细胞的免疫调节肽RP-182的脂肪酸衍生化和环化可提高抗肿瘤活性。
Mol Cancer Ther. 2024 Dec 3;23(12):1827-1841. doi: 10.1158/1535-7163.MCT-23-0790.
9
Machine learning for identifying tumor stemness genes and developing prognostic model in gastric cancer.用于识别胃癌肿瘤干性基因及构建预后模型的机器学习
Aging (Albany NY). 2024 Apr 12;16(7):6455-6477. doi: 10.18632/aging.205715.
10
Development of a customizable mouse backbone spectral flow cytometry panel to delineate immune cell populations in normal and tumor tissues.开发一种可定制的鼠标骨干光谱流式细胞术面板,以描绘正常和肿瘤组织中的免疫细胞群体。
Front Immunol. 2024 Mar 27;15:1374943. doi: 10.3389/fimmu.2024.1374943. eCollection 2024.
肿瘤浸润树突状细胞和自然杀伤细胞的细胞和基因特征可预测神经母细胞瘤的预后。
Nat Commun. 2020 Nov 25;11(1):5992. doi: 10.1038/s41467-020-19781-y.
4
Dendritic cells in the tumor microenvironment: prognostic and theranostic impact.肿瘤微环境中的树突状细胞:预后和治疗诊断影响。
Semin Immunol. 2020 Apr;48:101410. doi: 10.1016/j.smim.2020.101410. Epub 2020 Oct 1.
5
M2‑TAM subsets altered by lactic acid promote T‑cell apoptosis through the PD‑L1/PD‑1 pathway.乳酸改变的 M2-TAM 亚群通过 PD-L1/PD-1 通路促进 T 细胞凋亡。
Oncol Rep. 2020 Nov;44(5):1885-1894. doi: 10.3892/or.2020.7767. Epub 2020 Sep 15.
6
Prognostic role of baseline neutrophil-to-lymphocyte ratio in metastatic solid tumors.基线中性粒细胞与淋巴细胞比值在转移性实体瘤中的预后作用。
Mol Clin Oncol. 2020 Oct;13(4):25. doi: 10.3892/mco.2020.2095. Epub 2020 Jul 16.
7
Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.靶向肿瘤相关巨噬细胞和粒细胞性髓系来源的抑制细胞增强胆管癌的 PD-1 阻断。
J Clin Invest. 2020 Oct 1;130(10):5380-5396. doi: 10.1172/JCI137110.
8
CD163 tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes.CD163肿瘤相关巨噬细胞在乳腺癌患者中的积聚反映了局部分化信号和单核细胞的全身偏向性。
Clin Transl Immunology. 2020 Feb 13;9(2):e1108. doi: 10.1002/cti2.1108. eCollection 2020.
9
Circulating basophil count as a prognostic marker of tumor aggressiveness and survival outcomes in colorectal cancer.循环嗜碱性粒细胞计数作为结直肠癌肿瘤侵袭性和生存结果的预后标志物。
Clin Transl Med. 2020 Feb 10;9(1):6. doi: 10.1186/s40169-019-0255-4.
10
Dendritic cell subsets and locations.树突状细胞亚群和位置。
Int Rev Cell Mol Biol. 2019;348:1-68. doi: 10.1016/bs.ircmb.2019.07.004. Epub 2019 Sep 3.